淹死的鱼的个人主页 - 老虎社区

淹死的鱼

淹死的鱼

暂无个人介绍

IP属地：山东

60关注

6粉丝

2主题

0勋章

2021-08-05

$BioNTech SE(BNTX)$落袋一半仓位

2016-07-07

$3D系统(DDD)$加油

2020-10-13

$PolyPid Ltd.(PYPD)$有人么？

2020-08-01

$众巢医学(ZCMD)$没人玩了，半死不活

2020-09-04

$纳斯达克(.IXIC)$能收十字星么？

2017-09-05

$eBay(EBAY)$怎么回事？2015年7月前的k线和其余地方的差别这么大？

2017-08-07

$阿里巴巴(BABA)$网联的消息是利好么？

2023-09-22

$拼多多(PDD)$ 今天这么硬么

2021-08-10

$PolyPid Ltd.(PYPD)$再戳一戳

03-20

不急不急，看看戏

拼多多2023年Q4营收888.8亿元，调整后净利润同比增110%

2022-12-28

证明了有资本控制

新冠特效药背后的生意

2021-04-06

$Bellicum Pharmaceuticals, Inc.(BLCM)$加油加油^_^

2021-04-06

扶我起来，我还能行

2021-03-31

$C3.ai, Inc.(AI)$刚买就废了

2020-09-14

不会又得痿？

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":109525063074318,"uuid":"109525063074318","gmtCreate":1458215751755,"gmtModify":1617760699796,"name":"淹死的鱼","pinyin":"ysdyyansideyu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":60,"tweetSize":16,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":22,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.21","exceedPercentage":"60.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.39%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"山东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":286374205481056,"gmtCreate":1710943132619,"gmtModify":1710943134412,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"不急不急，看看戏","listText":"不急不急，看看戏","text":"不急不急，看看戏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/286374205481056","repostId":"1186413243","repostType":2,"repost":{"id":"1186413243","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1710930688,"share":"https://www.laohu8.com/m/news/1186413243?lang=&edition=full","pubTime":"2024-03-20 18:31","market":"us","language":"zh","title":"拼多多2023年Q4营收888.8亿元，调整后净利润同比增110%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186413243","media":"老虎资讯综合","summary":"第四季度调整后每ADS收益17.32元，市场预期11.28元。","content":"<html><head></head><body><p>3月20日周三，拼多多发布2023年Q4及全年业绩。</p><p>第四季度</p><ul style=\"\"><li><p>第四季度营收888.8亿元人民币，同比增长123%。市场预期798.74亿元，上年同期398.2亿元。</p></li><li><p>来自在线营销服务及其他服务的营收为486.756亿元（约合68.558亿美元），与2022年同期相比增长57%。</p></li><li><p>来自交易服务的营收为402.054亿元（约合56.628亿美元），与2022年同期相比增长357%。</p></li><li><p>第四季度归属于拼多多普通股股东的净利润为232.803亿元，同比增长146%。</p></li><li><p>不按美国通用会计准则，第四季度归属于拼多多普通股股东的净利润为254.765亿元，同比增长110%。</p></li><li><p>第四季度调整后每ADS收益17.32元，市场预期11.28元。</p></li></ul><p>2023年全年</p><ul style=\"\"><li><p>2023年，拼多多总营收为2476.392亿元，同比增长90%。</p></li><li><p>2023年，归属于拼多多普通股股东的净利润为600.265亿元，同比增长90%。</p></li><li><p>不按美国通用会计准则，2023年归属于拼多多普通股股东的净利润为678.993亿元，同比增长72%。</p></li></ul><p>拼多多集团全年研发投入为110亿元，其中，Q4研发费用同比增长19%，达到29亿元。拼多多董事长、联席首席执行官陈磊表示，“科技企业，研发为本。今年，我们将保持投入力度，为高质量发展探索、培育新质生产力，推动前沿技术在农业及制造业中的应用转化，支撑平台更高水平的高质量发展。”</p><p>截至发稿，拼多多盘前大涨15%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f2ce9442586747ba4546a9c56f9a7152\" title=\"\" tg-width=\"450\" tg-height=\"126\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>拼多多2023年Q4营收888.8亿元，调整后净利润同比增110%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n拼多多2023年Q4营收888.8亿元，调整后净利润同比增110%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-03-20 18:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>3月20日周三，拼多多发布2023年Q4及全年业绩。</p><p>第四季度</p><ul style=\"\"><li><p>第四季度营收888.8亿元人民币，同比增长123%。市场预期798.74亿元，上年同期398.2亿元。</p></li><li><p>来自在线营销服务及其他服务的营收为486.756亿元（约合68.558亿美元），与2022年同期相比增长57%。</p></li><li><p>来自交易服务的营收为402.054亿元（约合56.628亿美元），与2022年同期相比增长357%。</p></li><li><p>第四季度归属于拼多多普通股股东的净利润为232.803亿元，同比增长146%。</p></li><li><p>不按美国通用会计准则，第四季度归属于拼多多普通股股东的净利润为254.765亿元，同比增长110%。</p></li><li><p>第四季度调整后每ADS收益17.32元，市场预期11.28元。</p></li></ul><p>2023年全年</p><ul style=\"\"><li><p>2023年，拼多多总营收为2476.392亿元，同比增长90%。</p></li><li><p>2023年，归属于拼多多普通股股东的净利润为600.265亿元，同比增长90%。</p></li><li><p>不按美国通用会计准则，2023年归属于拼多多普通股股东的净利润为678.993亿元，同比增长72%。</p></li></ul><p>拼多多集团全年研发投入为110亿元，其中，Q4研发费用同比增长19%，达到29亿元。拼多多董事长、联席首席执行官陈磊表示，“科技企业，研发为本。今年，我们将保持投入力度，为高质量发展探索、培育新质生产力，推动前沿技术在农业及制造业中的应用转化，支撑平台更高水平的高质量发展。”</p><p>截至发稿，拼多多盘前大涨15%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f2ce9442586747ba4546a9c56f9a7152\" title=\"\" tg-width=\"450\" tg-height=\"126\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e42c16a083ab273c19aaae21cdb697a0","relate_stocks":{"PDD":"拼多多"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186413243","content_text":"3月20日周三，拼多多发布2023年Q4及全年业绩。第四季度第四季度营收888.8亿元人民币，同比增长123%。市场预期798.74亿元，上年同期398.2亿元。来自在线营销服务及其他服务的营收为486.756亿元（约合68.558亿美元），与2022年同期相比增长57%。来自交易服务的营收为402.054亿元（约合56.628亿美元），与2022年同期相比增长357%。第四季度归属于拼多多普通股股东的净利润为232.803亿元，同比增长146%。不按美国通用会计准则，第四季度归属于拼多多普通股股东的净利润为254.765亿元，同比增长110%。第四季度调整后每ADS收益17.32元，市场预期11.28元。2023年全年2023年，拼多多总营收为2476.392亿元，同比增长90%。2023年，归属于拼多多普通股股东的净利润为600.265亿元，同比增长90%。不按美国通用会计准则，2023年归属于拼多多普通股股东的净利润为678.993亿元，同比增长72%。拼多多集团全年研发投入为110亿元，其中，Q4研发费用同比增长19%，达到29亿元。拼多多董事长、联席首席执行官陈磊表示，“科技企业，研发为本。今年，我们将保持投入力度，为高质量发展探索、培育新质生产力，推动前沿技术在农业及制造业中的应用转化，支撑平台更高水平的高质量发展。”截至发稿，拼多多盘前大涨15%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":222631762186336,"gmtCreate":1695390016760,"gmtModify":1695390673149,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PDD\">$拼多多(PDD)$&nbsp;</a>今天这么硬么","listText":"<a href=\"https://laohu8.com/S/PDD\">$拼多多(PDD)$&nbsp;</a>今天这么硬么","text":"$拼多多(PDD)$ 今天这么硬么","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/222631762186336","isVote":1,"tweetType":1,"viewCount":593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":621612595,"gmtCreate":1672235337918,"gmtModify":1672235339710,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"证明了有资本控制","listText":"证明了有资本控制","text":"证明了有资本控制","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/621612595","repostId":"1154644492","repostType":4,"isVote":1,"tweetType":1,"viewCount":791,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":896820484,"gmtCreate":1628570329948,"gmtModify":1628570329948,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PYPD\">$PolyPid Ltd.(PYPD)$</a>再戳一戳","listText":"<a href=\"https://laohu8.com/S/PYPD\">$PolyPid Ltd.(PYPD)$</a>再戳一戳","text":"$PolyPid Ltd.(PYPD)$再戳一戳","images":[{"img":"https://static.tigerbbs.com/8314cc1b7516d6756d82a15ee9636314","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896820484","isVote":1,"tweetType":1,"viewCount":1646,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":890670414,"gmtCreate":1628117549038,"gmtModify":1628117549038,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>落袋一半仓位","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>落袋一半仓位","text":"$BioNTech SE(BNTX)$落袋一半仓位","images":[{"img":"https://static.tigerbbs.com/9fec318f5b97273ef4d693e46ec8f298","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890670414","isVote":1,"tweetType":1,"viewCount":1056,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":343273261,"gmtCreate":1617721169953,"gmtModify":1617721169953,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BLCM\">$Bellicum Pharmaceuticals, Inc.(BLCM)$</a>加油加油^_^","listText":"<a href=\"https://laohu8.com/S/BLCM\">$Bellicum Pharmaceuticals, Inc.(BLCM)$</a>加油加油^_^","text":"$Bellicum Pharmaceuticals, Inc.(BLCM)$加油加油^_^","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/343273261","isVote":1,"tweetType":1,"viewCount":1463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":343245444,"gmtCreate":1617720911588,"gmtModify":1617720911588,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"扶我起来，我还能行","listText":"扶我起来，我还能行","text":"扶我起来，我还能行","images":[{"img":"https://static.tigerbbs.com/6fcb7da6a7d489de5a5e89556a77e1e9","width":"750","height":"2352"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/343245444","isVote":1,"tweetType":1,"viewCount":1045,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":354748919,"gmtCreate":1617203266031,"gmtModify":1617203266031,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AI\">$C3.ai, Inc.(AI)$</a>刚买就废了","listText":"<a href=\"https://laohu8.com/S/AI\">$C3.ai, Inc.(AI)$</a>刚买就废了","text":"$C3.ai, Inc.(AI)$刚买就废了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354748919","isVote":1,"tweetType":1,"viewCount":1243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":309180188,"gmtCreate":1602597474044,"gmtModify":1703827120191,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PYPD\">$PolyPid Ltd.(PYPD)$</a>有人么？","listText":"<a href=\"https://laohu8.com/S/PYPD\">$PolyPid Ltd.(PYPD)$</a>有人么？","text":"$PolyPid Ltd.(PYPD)$有人么？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/309180188","isVote":1,"tweetType":1,"viewCount":2295,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0},"content":"还是没有人","text":"还是没有人","html":"还是没有人"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":972312605,"gmtCreate":1600096787707,"gmtModify":1703820334635,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"不会又得痿？","listText":"不会又得痿？","text":"不会又得痿？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/972312605","isVote":1,"tweetType":1,"viewCount":1021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":978287276,"gmtCreate":1599231791595,"gmtModify":1703818176401,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/.IXIC\">$纳斯达克(.IXIC)$</a>能收十字星么？","listText":"<a href=\"https://laohu8.com/S/.IXIC\">$纳斯达克(.IXIC)$</a>能收十字星么？","text":"$纳斯达克(.IXIC)$能收十字星么？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/978287276","isVote":1,"tweetType":1,"viewCount":1804,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3461571246357284","authorId":"3461571246357284","name":"三横","avatar":"https://static.tigerbbs.com/f758f3fd26a69f5421291bcbd4820d41","crmLevel":4,"crmLevelSwitch":0},"content":"万事皆有可能[捂脸]","text":"万事皆有可能[捂脸]","html":"万事皆有可能[捂脸]"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":942766772,"gmtCreate":1596216830396,"gmtModify":1704211856634,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZCMD\">$众巢医学(ZCMD)$</a>没人玩了，半死不活","listText":"<a href=\"https://laohu8.com/S/ZCMD\">$众巢医学(ZCMD)$</a>没人玩了，半死不活","text":"$众巢医学(ZCMD)$没人玩了，半死不活","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/942766772","isVote":1,"tweetType":1,"viewCount":1355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":93235,"gmtCreate":1504621788335,"gmtModify":1704880982511,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"$eBay(EBAY)$怎么回事？2015年7月前的k线和其余地方的差别这么大？","listText":"$eBay(EBAY)$怎么回事？2015年7月前的k线和其余地方的差别这么大？","text":"$eBay(EBAY)$怎么回事？2015年7月前的k线和其余地方的差别这么大？","images":[{"img":"https://static.laohu8.com/f5a50e40e7ec3fa182bf98402ea8ca89"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/93235","isVote":1,"tweetType":1,"viewCount":1183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":81753,"gmtCreate":1502115176433,"gmtModify":1704879713076,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"$阿里巴巴(BABA)$网联的消息是利好么？","listText":"$阿里巴巴(BABA)$网联的消息是利好么？","text":"$阿里巴巴(BABA)$网联的消息是利好么？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/81753","isVote":1,"tweetType":1,"viewCount":461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":19729,"gmtCreate":1467904228617,"gmtModify":1704871898937,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"$3D系统(DDD)$加油","listText":"$3D系统(DDD)$加油","text":"$3D系统(DDD)$加油","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/19729","isVote":1,"tweetType":1,"viewCount":827,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"39844973748057","authorId":"39844973748057","name":"七彩祥云","avatar":"https://static.tigerbbs.com/69b0f14bf22c2bc0071b589788de7cc4","crmLevel":1,"crmLevelSwitch":0},"content":"我玩的第一个动能股，好久不见","text":"我玩的第一个动能股，好久不见","html":"我玩的第一个动能股，好久不见"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":890670414,"gmtCreate":1628117549038,"gmtModify":1628117549038,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>落袋一半仓位","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>落袋一半仓位","text":"$BioNTech SE(BNTX)$落袋一半仓位","images":[{"img":"https://static.tigerbbs.com/9fec318f5b97273ef4d693e46ec8f298","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890670414","isVote":1,"tweetType":1,"viewCount":1056,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":19729,"gmtCreate":1467904228617,"gmtModify":1704871898937,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"$3D系统(DDD)$加油","listText":"$3D系统(DDD)$加油","text":"$3D系统(DDD)$加油","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/19729","isVote":1,"tweetType":1,"viewCount":827,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"39844973748057","authorId":"39844973748057","name":"七彩祥云","avatar":"https://static.tigerbbs.com/69b0f14bf22c2bc0071b589788de7cc4","crmLevel":1,"crmLevelSwitch":0},"content":"我玩的第一个动能股，好久不见","text":"我玩的第一个动能股，好久不见","html":"我玩的第一个动能股，好久不见"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":309180188,"gmtCreate":1602597474044,"gmtModify":1703827120191,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PYPD\">$PolyPid Ltd.(PYPD)$</a>有人么？","listText":"<a href=\"https://laohu8.com/S/PYPD\">$PolyPid Ltd.(PYPD)$</a>有人么？","text":"$PolyPid Ltd.(PYPD)$有人么？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/309180188","isVote":1,"tweetType":1,"viewCount":2295,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0},"content":"还是没有人","text":"还是没有人","html":"还是没有人"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":942766772,"gmtCreate":1596216830396,"gmtModify":1704211856634,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZCMD\">$众巢医学(ZCMD)$</a>没人玩了，半死不活","listText":"<a href=\"https://laohu8.com/S/ZCMD\">$众巢医学(ZCMD)$</a>没人玩了，半死不活","text":"$众巢医学(ZCMD)$没人玩了，半死不活","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/942766772","isVote":1,"tweetType":1,"viewCount":1355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":978287276,"gmtCreate":1599231791595,"gmtModify":1703818176401,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/.IXIC\">$纳斯达克(.IXIC)$</a>能收十字星么？","listText":"<a href=\"https://laohu8.com/S/.IXIC\">$纳斯达克(.IXIC)$</a>能收十字星么？","text":"$纳斯达克(.IXIC)$能收十字星么？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/978287276","isVote":1,"tweetType":1,"viewCount":1804,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3461571246357284","authorId":"3461571246357284","name":"三横","avatar":"https://static.tigerbbs.com/f758f3fd26a69f5421291bcbd4820d41","crmLevel":4,"crmLevelSwitch":0},"content":"万事皆有可能[捂脸]","text":"万事皆有可能[捂脸]","html":"万事皆有可能[捂脸]"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":93235,"gmtCreate":1504621788335,"gmtModify":1704880982511,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"$eBay(EBAY)$怎么回事？2015年7月前的k线和其余地方的差别这么大？","listText":"$eBay(EBAY)$怎么回事？2015年7月前的k线和其余地方的差别这么大？","text":"$eBay(EBAY)$怎么回事？2015年7月前的k线和其余地方的差别这么大？","images":[{"img":"https://static.laohu8.com/f5a50e40e7ec3fa182bf98402ea8ca89"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/93235","isVote":1,"tweetType":1,"viewCount":1183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":81753,"gmtCreate":1502115176433,"gmtModify":1704879713076,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"$阿里巴巴(BABA)$网联的消息是利好么？","listText":"$阿里巴巴(BABA)$网联的消息是利好么？","text":"$阿里巴巴(BABA)$网联的消息是利好么？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/81753","isVote":1,"tweetType":1,"viewCount":461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":222631762186336,"gmtCreate":1695390016760,"gmtModify":1695390673149,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PDD\">$拼多多(PDD)$&nbsp;</a>今天这么硬么","listText":"<a href=\"https://laohu8.com/S/PDD\">$拼多多(PDD)$&nbsp;</a>今天这么硬么","text":"$拼多多(PDD)$ 今天这么硬么","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/222631762186336","isVote":1,"tweetType":1,"viewCount":593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":896820484,"gmtCreate":1628570329948,"gmtModify":1628570329948,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PYPD\">$PolyPid Ltd.(PYPD)$</a>再戳一戳","listText":"<a href=\"https://laohu8.com/S/PYPD\">$PolyPid Ltd.(PYPD)$</a>再戳一戳","text":"$PolyPid Ltd.(PYPD)$再戳一戳","images":[{"img":"https://static.tigerbbs.com/8314cc1b7516d6756d82a15ee9636314","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896820484","isVote":1,"tweetType":1,"viewCount":1646,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":286374205481056,"gmtCreate":1710943132619,"gmtModify":1710943134412,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"不急不急，看看戏","listText":"不急不急，看看戏","text":"不急不急，看看戏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/286374205481056","repostId":"1186413243","repostType":2,"repost":{"id":"1186413243","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1710930688,"share":"https://www.laohu8.com/m/news/1186413243?lang=&edition=full","pubTime":"2024-03-20 18:31","market":"us","language":"zh","title":"拼多多2023年Q4营收888.8亿元，调整后净利润同比增110%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186413243","media":"老虎资讯综合","summary":"第四季度调整后每ADS收益17.32元，市场预期11.28元。","content":"<html><head></head><body><p>3月20日周三，拼多多发布2023年Q4及全年业绩。</p><p>第四季度</p><ul style=\"\"><li><p>第四季度营收888.8亿元人民币，同比增长123%。市场预期798.74亿元，上年同期398.2亿元。</p></li><li><p>来自在线营销服务及其他服务的营收为486.756亿元（约合68.558亿美元），与2022年同期相比增长57%。</p></li><li><p>来自交易服务的营收为402.054亿元（约合56.628亿美元），与2022年同期相比增长357%。</p></li><li><p>第四季度归属于拼多多普通股股东的净利润为232.803亿元，同比增长146%。</p></li><li><p>不按美国通用会计准则，第四季度归属于拼多多普通股股东的净利润为254.765亿元，同比增长110%。</p></li><li><p>第四季度调整后每ADS收益17.32元，市场预期11.28元。</p></li></ul><p>2023年全年</p><ul style=\"\"><li><p>2023年，拼多多总营收为2476.392亿元，同比增长90%。</p></li><li><p>2023年，归属于拼多多普通股股东的净利润为600.265亿元，同比增长90%。</p></li><li><p>不按美国通用会计准则，2023年归属于拼多多普通股股东的净利润为678.993亿元，同比增长72%。</p></li></ul><p>拼多多集团全年研发投入为110亿元，其中，Q4研发费用同比增长19%，达到29亿元。拼多多董事长、联席首席执行官陈磊表示，“科技企业，研发为本。今年，我们将保持投入力度，为高质量发展探索、培育新质生产力，推动前沿技术在农业及制造业中的应用转化，支撑平台更高水平的高质量发展。”</p><p>截至发稿，拼多多盘前大涨15%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f2ce9442586747ba4546a9c56f9a7152\" title=\"\" tg-width=\"450\" tg-height=\"126\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>拼多多2023年Q4营收888.8亿元，调整后净利润同比增110%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n拼多多2023年Q4营收888.8亿元，调整后净利润同比增110%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-03-20 18:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>3月20日周三，拼多多发布2023年Q4及全年业绩。</p><p>第四季度</p><ul style=\"\"><li><p>第四季度营收888.8亿元人民币，同比增长123%。市场预期798.74亿元，上年同期398.2亿元。</p></li><li><p>来自在线营销服务及其他服务的营收为486.756亿元（约合68.558亿美元），与2022年同期相比增长57%。</p></li><li><p>来自交易服务的营收为402.054亿元（约合56.628亿美元），与2022年同期相比增长357%。</p></li><li><p>第四季度归属于拼多多普通股股东的净利润为232.803亿元，同比增长146%。</p></li><li><p>不按美国通用会计准则，第四季度归属于拼多多普通股股东的净利润为254.765亿元，同比增长110%。</p></li><li><p>第四季度调整后每ADS收益17.32元，市场预期11.28元。</p></li></ul><p>2023年全年</p><ul style=\"\"><li><p>2023年，拼多多总营收为2476.392亿元，同比增长90%。</p></li><li><p>2023年，归属于拼多多普通股股东的净利润为600.265亿元，同比增长90%。</p></li><li><p>不按美国通用会计准则，2023年归属于拼多多普通股股东的净利润为678.993亿元，同比增长72%。</p></li></ul><p>拼多多集团全年研发投入为110亿元，其中，Q4研发费用同比增长19%，达到29亿元。拼多多董事长、联席首席执行官陈磊表示，“科技企业，研发为本。今年，我们将保持投入力度，为高质量发展探索、培育新质生产力，推动前沿技术在农业及制造业中的应用转化，支撑平台更高水平的高质量发展。”</p><p>截至发稿，拼多多盘前大涨15%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f2ce9442586747ba4546a9c56f9a7152\" title=\"\" tg-width=\"450\" tg-height=\"126\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e42c16a083ab273c19aaae21cdb697a0","relate_stocks":{"PDD":"拼多多"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186413243","content_text":"3月20日周三，拼多多发布2023年Q4及全年业绩。第四季度第四季度营收888.8亿元人民币，同比增长123%。市场预期798.74亿元，上年同期398.2亿元。来自在线营销服务及其他服务的营收为486.756亿元（约合68.558亿美元），与2022年同期相比增长57%。来自交易服务的营收为402.054亿元（约合56.628亿美元），与2022年同期相比增长357%。第四季度归属于拼多多普通股股东的净利润为232.803亿元，同比增长146%。不按美国通用会计准则，第四季度归属于拼多多普通股股东的净利润为254.765亿元，同比增长110%。第四季度调整后每ADS收益17.32元，市场预期11.28元。2023年全年2023年，拼多多总营收为2476.392亿元，同比增长90%。2023年，归属于拼多多普通股股东的净利润为600.265亿元，同比增长90%。不按美国通用会计准则，2023年归属于拼多多普通股股东的净利润为678.993亿元，同比增长72%。拼多多集团全年研发投入为110亿元，其中，Q4研发费用同比增长19%，达到29亿元。拼多多董事长、联席首席执行官陈磊表示，“科技企业，研发为本。今年，我们将保持投入力度，为高质量发展探索、培育新质生产力，推动前沿技术在农业及制造业中的应用转化，支撑平台更高水平的高质量发展。”截至发稿，拼多多盘前大涨15%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":621612595,"gmtCreate":1672235337918,"gmtModify":1672235339710,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"证明了有资本控制","listText":"证明了有资本控制","text":"证明了有资本控制","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/621612595","repostId":"1154644492","repostType":4,"repost":{"id":"1154644492","pubTimestamp":1672212244,"share":"https://www.laohu8.com/m/news/1154644492?lang=&edition=full","pubTime":"2022-12-28 15:24","market":"sh","language":"zh","title":"新冠特效药背后的生意","url":"https://stock-news.laohu8.com/highlight/detail?id=1154644492","media":"BT财经","summary":"特效药究竟能否终结这场持续三年的疫情？","content":"<html><head></head><body><p>文丨梦萧</p><p>近期新冠感染人数激增，新冠特效药成了大众关注的焦点。</p><p>12月26日消息，北京市近期计划在各社区卫生服务中心配置辉瑞新冠特效药Paxlovid（中文名：帕克斯洛维德），并组织全市社区医生抗病毒药物应用的紧急培训。</p><p>记者向北京市通州区一位社区医生求证核实，该医生确实参加了线上培训，主要是专家讲解了抗病毒药物类型和临床使用方法，并针对孕妇、儿童等特殊人群进行单独讲解如何用药，但此次培训未提到Paxlovid何时会配送至社区卫生服务中心。</p><p><img src=\"https://static.tigerbbs.com/272af1f9c8a90f4d141ec512f2d4ea7f\" tg-width=\"550\" tg-height=\"535\" referrerpolicy=\"no-referrer\"/></p><p>2022年2月11日，针对国内疫情反复的情况，国家药监局按照药品特别审批程序进行应急审评审批，附条件批准Paxlovid进口注册。此举直到12月也未引起公众太大关注，但在全面放开后，Paxlovid像莲花清瘟的风潮一样备受追崇，但是同时市场也有声音称需要冷静看待新冠特效药，因为它只是应急药，并不是国家终极目标的抗疫药品。</p><p>辉瑞也成功撬动了资本市场，从最新股价来看，51.83美元/股的股价处于历史高位，虽然相比最高点61.71美元/股有所下滑，却依然拥有2909亿美元的总市值，成为全球医药行业的翘楚。</p><p><img src=\"https://static.tigerbbs.com/214877404db9138499bfe9e776695437\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"/></p><p>财报显示，2022年一季度以来，Paxlovid在美国区域的处方增长了近5倍，在美国市场持续占据超过90%的市场份额，2022年上半年，仅Paxlovid的销售额已达96亿美元。截至目前，已开出超过390万张处方，销售额还在不断增长。2020年辉瑞总营收为416.5亿美元，而2021年的总营收为812.9亿美元，同比激增95.2%。</p><p>可见，新冠特效药是门好生意，但新冠特效药究竟能否终结这场持续三年的疫情？</p><p><b>辉瑞特效药医不自治？</b></p><p>新冠特效药赚钱能力强是不争的事实，药效到底如何，却褒贬不一。</p><p>北大医院一位不愿具名的主任医师介绍称，Paxlovid之所以是附条件进口，是因为它是紧急批复的药品，大概率是没有经过三期临床试验的，“Paxlovid药理上属于病毒阻断药，之前常用在艾滋病晚期阻断，其最大的副作用是容易造成肝损伤，治疗新冠的原理也是从艾滋病阻断药改良过来的，在国内通过三期临床试验的可能性不大，药理学专家一般都是辩证的看这个药品（既看中它的药效，又警惕带来的副作用），国家的用药指导意见也还没出台，它不是普及药品，暂时也不是国家允许普及的药品。”</p><p>该医师介绍称，目前该药一般用于新冠感染引发的危重症患者。</p><p>网络上，网友对Paxlovid的认可度并不高，北京某疫情较为严重的小区500人的业主大群内，有对Paxlovid的激烈讨论，大部分业主都认为其并没有传说中的那么神奇，不然也不会有自己的高管去世。之所以成为市场的热炒药品，是因为有资本的推波助澜。</p><p><img src=\"https://static.tigerbbs.com/80833cda7c8d5b3c39a88784311a11ce\" tg-width=\"550\" tg-height=\"583\" referrerpolicy=\"no-referrer\"/></p><p>尽管Paxlovid的市场认可度不高，但在1药网一度被炒到2980元一盒的天价，比之前医保采购价2300元要高出一截。据悉，每盒Paxlovid包含20片奈玛特韦和10片利托那韦。以此计算，每片Paxlovid的价格约为100元，是名副其实的“天价药”。但不知何种原因，目前1药网相关预售页面已经删除了。</p><p><img src=\"https://static.tigerbbs.com/9f311b2d58474605c83a717e22a64cf4\" tg-width=\"550\" tg-height=\"914\" referrerpolicy=\"no-referrer\"/></p><p>《柳叶刀》的权威解读</p><p>要想了解Paxlovid的真实疗效，还需要从国际权威医学学术杂志《柳叶刀》内寻找答案。</p><p>据《柳叶刀》撰文显示，针对新冠特效药其在香港进行了为期4个月的真实调研，调研时间为2022年2月26日至6月26日，调研样本为11847例，这些样本服用过Molnupiravir或Paxlovid，且大多属于年龄偏大的高危人群，他们有未完成疫苗接种的共同点。通过这些患者的真实记录来分析两种药物的实际表现。</p><p>2022年10月8日，《柳叶刀》发布本次调研的报告，报告显示，Molnupiravir治疗组的全因死亡率为17.9/100000人日，相比对照组降低了24%。而Paxlovid表现相对优异一些，数据为治疗组的全因死亡率4.2/100000人日，相比对照组降低66%。</p><p>肯定了新冠特效药Paxlovid疗效的同时，《柳叶刀》还指出，Paxlovid虽然在众多新冠药物中有明显优势，但也不是“包治百病，药到病除”的特效药，它的使用范围有明显的界定，在临床使用中有诸多限制和不足，同时也有一定的副作用。</p><p>调研报告显示，首先，Paxlovid作为处方药，在未经医生处方的情况下自行服用的风险很大。其次是未被授权用作新冠病毒暴露前或暴露后的预防，也就是说不能作为预防新冠的药物。未被授权用于严重或者危症新冠患者的初始治疗以及未被授权超过5天连续使用。报告提示临床试验中Paxlovid常见不良反应众多，包括味觉改变、恶心、高血压、肌肉疼痛、腹痛、腹泻等，不建议患有严重肝病和肾病的患者服用，这和被神化的“特效”有本质差别。</p><p>《柳叶刀》最明显的结论是Paxlovid等新冠特效药，对65岁以下健康人群效果并不显著。以国家卫健委老龄司发布的《2021年度国家老龄事业发展公报》数据来看，2021年全国65岁以上老年人口达20056万人，占总人口的14.2%，在全国总人口中依然处于偏低比例，也无法成为全社会层面大力普及的药物。</p><p>唐山某公立医院主任医师尹凡认为Paxlovid虽然对部分新冠病人有一定疗效，但不应该被神化，“它的药理性决定其本身的副作用很明显，不适应所有人群。目前之所以被热炒，是因为感染人群突然增多，大家的心理焦虑被厂家利用。”据介绍，尹凡自己的家人也有重症患者，但并没有选择Paxlovid。“没敢用那个药，主要还是担心副作用太大。”</p><p>而另外一种新冠特效药阿兹夫定，在2022年8月获批成为首个上市的国产新冠特效药，定价为每瓶270元，每瓶35片，每片1mg。被列入《第九版新冠诊疗方案》，用于治疗普通型新冠肺炎成年患者。据BT财经了解到，该药在医药电商上市不久就下架了，具体原因不明，有业内人士推测或和该药是处方药有关。</p><p>Paxlovid和阿兹夫定是目前国内仅有的两款新冠口服药，也被冠以“新冠特效药”的称谓。两者却都同时上演了“闪上”又“闪退”的闹剧，让众多期待新冠特效药的消费者茫然不知所措，这直接暴露出，新冠药物在目前还没有确立如何使用、何种人群适用、是否可以线上开处方的清晰界限，这些问题不解决，就很难全民普及和推广。</p><p><b>阿兹夫定难成救星</b></p><p>作为国内唯一一种新冠特效药，真实生物生产的阿兹夫定定价是比较亲民的，价格不到Paxlovid的1/10。据《北京商报》报道，阿兹夫定片的价格是每瓶不到300元，以每瓶35片计算，每片约8.5元。</p><p>真实生物于8月2日发文称，阿兹夫定片已经正式进入投产阶段，目前公司平顶山生产基地年产能是10亿片，未来有望实现30亿片的年产能。即便以现在的产能来计算，10亿片的年产能，将为真实生物带来近90亿元的销售额。</p><p>根据真实生物的财务数据可知，2020年、2021年及2022年前5月，真实生物的收入分别是6.8万元、137.6万元、845.1万元，期间亏损分别是1.51亿元、1.97亿元、2.18亿元，前者数百万元的营收和预期的90亿元营收相比，可谓一飞冲天。</p><p>但作为首款被批准的国产新冠口服药，阿兹夫定目前尚未在学术期刊上公开关于新冠治疗的研究数据，BT财经只能从其生产厂家真实生物的IPO申请文件和药物试验登记网站获得其三期临床试验部分信息，而这些数据只是真实生物用来上市的数据，数据主要来自商业属性浓厚IPO文件，缺乏来自学术期刊的研究，导致试验数据不足，部分数据或存疑，最终数据的真实性有待考证。</p><p><img src=\"https://static.tigerbbs.com/f86cb37472ebbcf21a9a8e39e95f2937\" tg-width=\"550\" tg-height=\"552\" referrerpolicy=\"no-referrer\"/></p><p>比如，真实生物的中症新冠患者的研究数据严重偏少，在俄罗斯仅有314名样本，从这些数据的样本中可以看出，阿兹夫定的疗效比较显著，在用药7天后，用药组40.43%的患者症状有改善，而安慰剂组只有10.87%。数据看似喜人，但因缺乏足够的样本支撑，并不被更多的业内人士所接受。</p><p>同样，阿兹夫定在巴西招募的样本，也只有140例，以如此偏低的数据样本得出结论，显然有违医学常理。作为对比，Paxlovid的临床试验招募了2246名受试者，是阿兹夫定受试者的5倍，Molnupiravir的临床试验招募了1400余人，是阿兹夫定受试者的3倍。国家食品药品监督管理总局在2013年颁布的《药品注册管理办法》中规定，三期临床的最低样本为300例，阿兹夫定虽然达到了这一标准，却因为样本基数太小而被医学界质疑。</p><p>阿兹夫定之所以被质疑，是因为根据阿兹夫定的上市审评报告，其遗传毒性和生殖毒性无法忽视。除此之外阿兹夫定还有诸多不良反应，包括头痛、困倦的神经系统疾病、转氨酶升高，血尿酸水平升高的肝肾功能异常以及恶心、呕吐、腹泻等胃肠道反应，同样属于副作用较多的药品范围。</p><p>BT财经了解到，在互联网医院可以轻松购买阿兹夫定，只需提供核酸或抗原阳性结果照片，就可一键下单。而作为处方药，这样的销售显然是有违国内处方药的相关规定。负责阿兹夫定商业化的复星医药称，目前正与多家互联网医疗平台接洽合作，多渠道实现可及性，进一步满足新冠病毒感染患者居家治疗需求。</p><p>一个利好消息是，2022年12月12日，国务院应对新型冠状病毒肺炎疫情联防联控机制医疗救治组发布《关于做好新冠肺炎互联网医疗服务的通知》，明确医疗机构可在线开具治疗新冠肺炎相关症状的处方，鼓励委托符合条件的第三方将药品配送到患者家中。这是对互联网医院的一次开闸信号，或将改变处方药未来的销售模式。</p><p>虽然真实生物拿下了国产新冠口服药首药的桂冠，但其面临的竞争并不小，众多药企同样看中了新冠药物的巨大市场，开始紧随其后，旺山旺水/君实生物VV116、开拓药业普克鲁胺的进展较快，有望成为下一款获批的国产抗新冠口服药。</p><p>普克鲁胺和VV116目前均处在III期的不同阶段。2022年4月，开拓药业公布了普克鲁胺治疗轻中症的III期全球多中心临床试验最终关键结果。数据显示，普克鲁胺有效降低新冠患者的住院/死亡率。2022年5月，君实生物披露公告称，VV116在一项对比Paxlovid用于轻中度新型冠状病毒肺炎早期治疗的III期注册临床研究。这两家的三期临床数据样本远高于真实生物，这对真实生物是巨大挑战。</p><p>“当时真实生物能拿下第一个获批的新冠口服药，出乎业内很多人的意料，因为无论是从财力还是实力上看，君实生物、前沿生物还是先声药业以及开拓药业都比他有实力，而新冠随着病毒毒株的变异，未来将长期存在，新冠药物的市场极为庞大。”一位不愿具名的医药行业人士对真实生物能拿下第一个审批，表示很意外。</p><p>值得一提的是，君实生物和开拓药业都是上市公司，其雄厚的财力支持，恐远非真实生物可比，真实生物目前尚在谋求上市。截至12月26日，君实生物的总市值347亿港元，开拓药业的总市值为49亿港元，其中君实生物的股价上涨4.14%，股价为35.25港元/股。</p><p><img src=\"https://static.tigerbbs.com/f28b5903af578c9fa16299b5ed81e89d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"/></p><p>目前来看，阿兹夫定的口碑并未因为低价而达到预期，这或和真实生物尚未上市，自身实力受限有一定关系，但其他药企纷纷进入，对国产新冠口服药将是极大的推进。</p><p><b>新冠药物前景广阔</b></p><p>2022年1月19日，世卫组织突发卫生事件规划执行主任Mike Ryan，在达沃斯世界经济论坛的在线会议上指出，奥密克戎迅速传播之下，很可能还会出现新的变异株，经过变异后，新冠病毒彻底消失的可能性基本为零，人类终究要和它共存。这意味着未来新冠药物将是全球人类都几乎必备的药品，这无疑催生了巨大的市场需求，相关行业前景看好。</p><p>疫情以来新冠相关药物的需求增长旺盛，市场规模增长迅猛。据方正证券评估，中国未来三年将完成覆盖10%总人口的药物储备，大概有1.5亿人拥有新冠口服药的储备。2023-2025年采购量将达到3000万份、5000万份、6000万份，但因行业竞争和研发力度的加大，新冠口服药单价或呈现逐年下降趋势，对应价格为600元/疗程、300元/疗程、150元/疗程，3年合计依然高达420亿元。</p><p>对于国内第一个获批的阿兹夫定特效药，首创证券给出的市场空间为30亿元左右，上游原料药市场按5%-10%计算约为1.5亿-3亿元，下游分销配送市场按5%-8%计算约为1.5亿-2.4亿元。如果按方正证券的预测，420亿元以上的市场规模中上游原料药市场约为21亿-42亿元，下游分销配送市场约为21亿-34亿元。其他相关产业链也均能从中获得一定收益，对整个相关产业链都有一定的推动作用。</p><p>而针对一年多以来，仅有真实生物的阿兹夫定获批的事实，有业内人士认为这和国内药企的基础研究能力相对较弱有关。“真实生物的阿兹夫定成为国内研发出第一款新冠口服药，也只是万里长征第一步，考虑到国内巨大市场需求，未来新冠口服药领域的跨企业合作、对外授权和CXO可能性很大。”</p><p>不可否认的是，国内药企的相关动作并不快，但对药企来说，新冠药物将是难得的弯道超车机会。毕竟在新冠灭活疫苗的相关领域，已经成功催生出两家年盈利数百亿的药企，而从市场体量上看，新冠口服药的利润相比疫苗只高不低。</p><p>即便短期内的新冠药物因为研发投入太大而无法盈利，但通过热点营销带来口碑的提升以及在资本市场关注度的提升，都对医药行业发展有不可估量的促进作用。此外还带动了国内药企的研发投入大大增加，推动了临床试验以及相关人才的积累，改善了国内药企的应急能力。</p><p>目前辉瑞和真实生物已经走在前面，众多药企也在争先恐后进入赛道，未来通过良性竞争，真正对新冠有特效的国产低价药品或在不久后问世，这对饱受疫情折磨的国人来说，将是莫大的福音。</p></body></html>","source":"lsy1588993976395","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新冠特效药背后的生意</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新冠特效药背后的生意\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-28 15:24 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/tech/csj/2022-12-28/doc-imxyenxk9430994.shtml><strong>BT财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>文丨梦萧近期新冠感染人数激增，新冠特效药成了大众关注的焦点。12月26日消息，北京市近期计划在各社区卫生服务中心配置辉瑞新冠特效药Paxlovid（中文名：帕克斯洛维德），并组织全市社区医生抗病毒药物应用的紧急培训。记者向北京市通州区一位社区医生求证核实，该医生确实参加了线上培训，主要是专家讲解了抗病毒药物类型和临床使用方法，并针对孕妇、儿童等特殊人群进行单独讲解如何用药，但此次培训未提到...</p>\n\n<a href=\"https://finance.sina.com.cn/tech/csj/2022-12-28/doc-imxyenxk9430994.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/86caee6b0aec6bd2902dea91a4ecb3e5","relate_stocks":{"09939":"开拓药业-B","PFE":"辉瑞","01877":"君实生物"},"source_url":"https://finance.sina.com.cn/tech/csj/2022-12-28/doc-imxyenxk9430994.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154644492","content_text":"文丨梦萧近期新冠感染人数激增，新冠特效药成了大众关注的焦点。12月26日消息，北京市近期计划在各社区卫生服务中心配置辉瑞新冠特效药Paxlovid（中文名：帕克斯洛维德），并组织全市社区医生抗病毒药物应用的紧急培训。记者向北京市通州区一位社区医生求证核实，该医生确实参加了线上培训，主要是专家讲解了抗病毒药物类型和临床使用方法，并针对孕妇、儿童等特殊人群进行单独讲解如何用药，但此次培训未提到Paxlovid何时会配送至社区卫生服务中心。2022年2月11日，针对国内疫情反复的情况，国家药监局按照药品特别审批程序进行应急审评审批，附条件批准Paxlovid进口注册。此举直到12月也未引起公众太大关注，但在全面放开后，Paxlovid像莲花清瘟的风潮一样备受追崇，但是同时市场也有声音称需要冷静看待新冠特效药，因为它只是应急药，并不是国家终极目标的抗疫药品。辉瑞也成功撬动了资本市场，从最新股价来看，51.83美元/股的股价处于历史高位，虽然相比最高点61.71美元/股有所下滑，却依然拥有2909亿美元的总市值，成为全球医药行业的翘楚。财报显示，2022年一季度以来，Paxlovid在美国区域的处方增长了近5倍，在美国市场持续占据超过90%的市场份额，2022年上半年，仅Paxlovid的销售额已达96亿美元。截至目前，已开出超过390万张处方，销售额还在不断增长。2020年辉瑞总营收为416.5亿美元，而2021年的总营收为812.9亿美元，同比激增95.2%。可见，新冠特效药是门好生意，但新冠特效药究竟能否终结这场持续三年的疫情？辉瑞特效药医不自治？新冠特效药赚钱能力强是不争的事实，药效到底如何，却褒贬不一。北大医院一位不愿具名的主任医师介绍称，Paxlovid之所以是附条件进口，是因为它是紧急批复的药品，大概率是没有经过三期临床试验的，“Paxlovid药理上属于病毒阻断药，之前常用在艾滋病晚期阻断，其最大的副作用是容易造成肝损伤，治疗新冠的原理也是从艾滋病阻断药改良过来的，在国内通过三期临床试验的可能性不大，药理学专家一般都是辩证的看这个药品（既看中它的药效，又警惕带来的副作用），国家的用药指导意见也还没出台，它不是普及药品，暂时也不是国家允许普及的药品。”该医师介绍称，目前该药一般用于新冠感染引发的危重症患者。网络上，网友对Paxlovid的认可度并不高，北京某疫情较为严重的小区500人的业主大群内，有对Paxlovid的激烈讨论，大部分业主都认为其并没有传说中的那么神奇，不然也不会有自己的高管去世。之所以成为市场的热炒药品，是因为有资本的推波助澜。尽管Paxlovid的市场认可度不高，但在1药网一度被炒到2980元一盒的天价，比之前医保采购价2300元要高出一截。据悉，每盒Paxlovid包含20片奈玛特韦和10片利托那韦。以此计算，每片Paxlovid的价格约为100元，是名副其实的“天价药”。但不知何种原因，目前1药网相关预售页面已经删除了。《柳叶刀》的权威解读要想了解Paxlovid的真实疗效，还需要从国际权威医学学术杂志《柳叶刀》内寻找答案。据《柳叶刀》撰文显示，针对新冠特效药其在香港进行了为期4个月的真实调研，调研时间为2022年2月26日至6月26日，调研样本为11847例，这些样本服用过Molnupiravir或Paxlovid，且大多属于年龄偏大的高危人群，他们有未完成疫苗接种的共同点。通过这些患者的真实记录来分析两种药物的实际表现。2022年10月8日，《柳叶刀》发布本次调研的报告，报告显示，Molnupiravir治疗组的全因死亡率为17.9/100000人日，相比对照组降低了24%。而Paxlovid表现相对优异一些，数据为治疗组的全因死亡率4.2/100000人日，相比对照组降低66%。肯定了新冠特效药Paxlovid疗效的同时，《柳叶刀》还指出，Paxlovid虽然在众多新冠药物中有明显优势，但也不是“包治百病，药到病除”的特效药，它的使用范围有明显的界定，在临床使用中有诸多限制和不足，同时也有一定的副作用。调研报告显示，首先，Paxlovid作为处方药，在未经医生处方的情况下自行服用的风险很大。其次是未被授权用作新冠病毒暴露前或暴露后的预防，也就是说不能作为预防新冠的药物。未被授权用于严重或者危症新冠患者的初始治疗以及未被授权超过5天连续使用。报告提示临床试验中Paxlovid常见不良反应众多，包括味觉改变、恶心、高血压、肌肉疼痛、腹痛、腹泻等，不建议患有严重肝病和肾病的患者服用，这和被神化的“特效”有本质差别。《柳叶刀》最明显的结论是Paxlovid等新冠特效药，对65岁以下健康人群效果并不显著。以国家卫健委老龄司发布的《2021年度国家老龄事业发展公报》数据来看，2021年全国65岁以上老年人口达20056万人，占总人口的14.2%，在全国总人口中依然处于偏低比例，也无法成为全社会层面大力普及的药物。唐山某公立医院主任医师尹凡认为Paxlovid虽然对部分新冠病人有一定疗效，但不应该被神化，“它的药理性决定其本身的副作用很明显，不适应所有人群。目前之所以被热炒，是因为感染人群突然增多，大家的心理焦虑被厂家利用。”据介绍，尹凡自己的家人也有重症患者，但并没有选择Paxlovid。“没敢用那个药，主要还是担心副作用太大。”而另外一种新冠特效药阿兹夫定，在2022年8月获批成为首个上市的国产新冠特效药，定价为每瓶270元，每瓶35片，每片1mg。被列入《第九版新冠诊疗方案》，用于治疗普通型新冠肺炎成年患者。据BT财经了解到，该药在医药电商上市不久就下架了，具体原因不明，有业内人士推测或和该药是处方药有关。Paxlovid和阿兹夫定是目前国内仅有的两款新冠口服药，也被冠以“新冠特效药”的称谓。两者却都同时上演了“闪上”又“闪退”的闹剧，让众多期待新冠特效药的消费者茫然不知所措，这直接暴露出，新冠药物在目前还没有确立如何使用、何种人群适用、是否可以线上开处方的清晰界限，这些问题不解决，就很难全民普及和推广。阿兹夫定难成救星作为国内唯一一种新冠特效药，真实生物生产的阿兹夫定定价是比较亲民的，价格不到Paxlovid的1/10。据《北京商报》报道，阿兹夫定片的价格是每瓶不到300元，以每瓶35片计算，每片约8.5元。真实生物于8月2日发文称，阿兹夫定片已经正式进入投产阶段，目前公司平顶山生产基地年产能是10亿片，未来有望实现30亿片的年产能。即便以现在的产能来计算，10亿片的年产能，将为真实生物带来近90亿元的销售额。根据真实生物的财务数据可知，2020年、2021年及2022年前5月，真实生物的收入分别是6.8万元、137.6万元、845.1万元，期间亏损分别是1.51亿元、1.97亿元、2.18亿元，前者数百万元的营收和预期的90亿元营收相比，可谓一飞冲天。但作为首款被批准的国产新冠口服药，阿兹夫定目前尚未在学术期刊上公开关于新冠治疗的研究数据，BT财经只能从其生产厂家真实生物的IPO申请文件和药物试验登记网站获得其三期临床试验部分信息，而这些数据只是真实生物用来上市的数据，数据主要来自商业属性浓厚IPO文件，缺乏来自学术期刊的研究，导致试验数据不足，部分数据或存疑，最终数据的真实性有待考证。比如，真实生物的中症新冠患者的研究数据严重偏少，在俄罗斯仅有314名样本，从这些数据的样本中可以看出，阿兹夫定的疗效比较显著，在用药7天后，用药组40.43%的患者症状有改善，而安慰剂组只有10.87%。数据看似喜人，但因缺乏足够的样本支撑，并不被更多的业内人士所接受。同样，阿兹夫定在巴西招募的样本，也只有140例，以如此偏低的数据样本得出结论，显然有违医学常理。作为对比，Paxlovid的临床试验招募了2246名受试者，是阿兹夫定受试者的5倍，Molnupiravir的临床试验招募了1400余人，是阿兹夫定受试者的3倍。国家食品药品监督管理总局在2013年颁布的《药品注册管理办法》中规定，三期临床的最低样本为300例，阿兹夫定虽然达到了这一标准，却因为样本基数太小而被医学界质疑。阿兹夫定之所以被质疑，是因为根据阿兹夫定的上市审评报告，其遗传毒性和生殖毒性无法忽视。除此之外阿兹夫定还有诸多不良反应，包括头痛、困倦的神经系统疾病、转氨酶升高，血尿酸水平升高的肝肾功能异常以及恶心、呕吐、腹泻等胃肠道反应，同样属于副作用较多的药品范围。BT财经了解到，在互联网医院可以轻松购买阿兹夫定，只需提供核酸或抗原阳性结果照片，就可一键下单。而作为处方药，这样的销售显然是有违国内处方药的相关规定。负责阿兹夫定商业化的复星医药称，目前正与多家互联网医疗平台接洽合作，多渠道实现可及性，进一步满足新冠病毒感染患者居家治疗需求。一个利好消息是，2022年12月12日，国务院应对新型冠状病毒肺炎疫情联防联控机制医疗救治组发布《关于做好新冠肺炎互联网医疗服务的通知》，明确医疗机构可在线开具治疗新冠肺炎相关症状的处方，鼓励委托符合条件的第三方将药品配送到患者家中。这是对互联网医院的一次开闸信号，或将改变处方药未来的销售模式。虽然真实生物拿下了国产新冠口服药首药的桂冠，但其面临的竞争并不小，众多药企同样看中了新冠药物的巨大市场，开始紧随其后，旺山旺水/君实生物VV116、开拓药业普克鲁胺的进展较快，有望成为下一款获批的国产抗新冠口服药。普克鲁胺和VV116目前均处在III期的不同阶段。2022年4月，开拓药业公布了普克鲁胺治疗轻中症的III期全球多中心临床试验最终关键结果。数据显示，普克鲁胺有效降低新冠患者的住院/死亡率。2022年5月，君实生物披露公告称，VV116在一项对比Paxlovid用于轻中度新型冠状病毒肺炎早期治疗的III期注册临床研究。这两家的三期临床数据样本远高于真实生物，这对真实生物是巨大挑战。“当时真实生物能拿下第一个获批的新冠口服药，出乎业内很多人的意料，因为无论是从财力还是实力上看，君实生物、前沿生物还是先声药业以及开拓药业都比他有实力，而新冠随着病毒毒株的变异，未来将长期存在，新冠药物的市场极为庞大。”一位不愿具名的医药行业人士对真实生物能拿下第一个审批，表示很意外。值得一提的是，君实生物和开拓药业都是上市公司，其雄厚的财力支持，恐远非真实生物可比，真实生物目前尚在谋求上市。截至12月26日，君实生物的总市值347亿港元，开拓药业的总市值为49亿港元，其中君实生物的股价上涨4.14%，股价为35.25港元/股。目前来看，阿兹夫定的口碑并未因为低价而达到预期，这或和真实生物尚未上市，自身实力受限有一定关系，但其他药企纷纷进入，对国产新冠口服药将是极大的推进。新冠药物前景广阔2022年1月19日，世卫组织突发卫生事件规划执行主任Mike Ryan，在达沃斯世界经济论坛的在线会议上指出，奥密克戎迅速传播之下，很可能还会出现新的变异株，经过变异后，新冠病毒彻底消失的可能性基本为零，人类终究要和它共存。这意味着未来新冠药物将是全球人类都几乎必备的药品，这无疑催生了巨大的市场需求，相关行业前景看好。疫情以来新冠相关药物的需求增长旺盛，市场规模增长迅猛。据方正证券评估，中国未来三年将完成覆盖10%总人口的药物储备，大概有1.5亿人拥有新冠口服药的储备。2023-2025年采购量将达到3000万份、5000万份、6000万份，但因行业竞争和研发力度的加大，新冠口服药单价或呈现逐年下降趋势，对应价格为600元/疗程、300元/疗程、150元/疗程，3年合计依然高达420亿元。对于国内第一个获批的阿兹夫定特效药，首创证券给出的市场空间为30亿元左右，上游原料药市场按5%-10%计算约为1.5亿-3亿元，下游分销配送市场按5%-8%计算约为1.5亿-2.4亿元。如果按方正证券的预测，420亿元以上的市场规模中上游原料药市场约为21亿-42亿元，下游分销配送市场约为21亿-34亿元。其他相关产业链也均能从中获得一定收益，对整个相关产业链都有一定的推动作用。而针对一年多以来，仅有真实生物的阿兹夫定获批的事实，有业内人士认为这和国内药企的基础研究能力相对较弱有关。“真实生物的阿兹夫定成为国内研发出第一款新冠口服药，也只是万里长征第一步，考虑到国内巨大市场需求，未来新冠口服药领域的跨企业合作、对外授权和CXO可能性很大。”不可否认的是，国内药企的相关动作并不快，但对药企来说，新冠药物将是难得的弯道超车机会。毕竟在新冠灭活疫苗的相关领域，已经成功催生出两家年盈利数百亿的药企，而从市场体量上看，新冠口服药的利润相比疫苗只高不低。即便短期内的新冠药物因为研发投入太大而无法盈利，但通过热点营销带来口碑的提升以及在资本市场关注度的提升，都对医药行业发展有不可估量的促进作用。此外还带动了国内药企的研发投入大大增加，推动了临床试验以及相关人才的积累，改善了国内药企的应急能力。目前辉瑞和真实生物已经走在前面，众多药企也在争先恐后进入赛道，未来通过良性竞争，真正对新冠有特效的国产低价药品或在不久后问世，这对饱受疫情折磨的国人来说，将是莫大的福音。","news_type":1},"isVote":1,"tweetType":1,"viewCount":791,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":343273261,"gmtCreate":1617721169953,"gmtModify":1617721169953,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BLCM\">$Bellicum Pharmaceuticals, Inc.(BLCM)$</a>加油加油^_^","listText":"<a href=\"https://laohu8.com/S/BLCM\">$Bellicum Pharmaceuticals, Inc.(BLCM)$</a>加油加油^_^","text":"$Bellicum Pharmaceuticals, Inc.(BLCM)$加油加油^_^","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/343273261","isVote":1,"tweetType":1,"viewCount":1463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":343245444,"gmtCreate":1617720911588,"gmtModify":1617720911588,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"扶我起来，我还能行","listText":"扶我起来，我还能行","text":"扶我起来，我还能行","images":[{"img":"https://static.tigerbbs.com/6fcb7da6a7d489de5a5e89556a77e1e9","width":"750","height":"2352"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/343245444","isVote":1,"tweetType":1,"viewCount":1045,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":354748919,"gmtCreate":1617203266031,"gmtModify":1617203266031,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AI\">$C3.ai, Inc.(AI)$</a>刚买就废了","listText":"<a href=\"https://laohu8.com/S/AI\">$C3.ai, Inc.(AI)$</a>刚买就废了","text":"$C3.ai, Inc.(AI)$刚买就废了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354748919","isVote":1,"tweetType":1,"viewCount":1243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":972312605,"gmtCreate":1600096787707,"gmtModify":1703820334635,"author":{"id":"109525063074318","authorId":"109525063074318","name":"淹死的鱼","avatar":"https://static.tigerbbs.com/a42812c0a639ebfd0bffe0639042ba55","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"不会又得痿？","listText":"不会又得痿？","text":"不会又得痿？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/972312605","isVote":1,"tweetType":1,"viewCount":1021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}